KUALA LUMPUR – Clinigen Group plc, the global pharmaceutical and services company, has launched its Malaysian business with an office here.
“Pharmaceutical and biotechnology companies are increasingly looking for specialist partners to work with them in Asia. The opening of our Malaysian office provides Clinigen with greater opportunities to offer our customers at both a global and local level,” said Clinigen’s Group ehief executive officer, Shaun Chilton.
According to a statement, the new office is part of Clinigen’s strategy to expand its footprint in Southeast Asia, an important market for the Group.
The Group’s strategy in Malaysia is to become the vendor of choice for the sourcing and supply of medicines to its customers, providing additional infrastructure to support its mission to deliver the right medicine to the right patient and the right time.
The immediate aim is to expand access to unlicensed medicines by extending the reach of the Group’s Unlicensed Medicines exclusive supply agreements and on-demand service, as well as offering Clinigen’s Clinical Services to its customers.
In addition, Clinigen’s presence will increase its capability in the supply and distribution of products from the Group’s portfolio of licensed medicines and makes Clinigen a more attractive partner for pharma companies looking to commercialise products outside of their home geographies, using Clinigen’s regulatory expertise.
The opening of the Malaysian office further expands its international supply chain and operational network as Clinigen employs over 1,150 people globally, across 14 international locations.
More details at the company's website here.– Bernama, December 2, 2020
.jpeg)
.jpg)
